Clinical Trial

Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

Study acronym: SEMA-CKM
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 20, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.
Trial Details
NCT Number NCT07424430
Lead Sponsor LMC Diabetes & Endocrinology Ltd.
Conditions Diabetes (DM), Type 2 Diabetes, Obesity (Disorder)
Enrollment 400 participants
Start Date 2026-03
Primary Completion 2026-04 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-20